Market Cap 110.16B
Revenue (ttm) 11.02B
Net Income (ttm) -535.60M
EPS (ttm) N/A
PE Ratio 28.04
Forward PE 26.84
Profit Margin -4.86%
Debt to Equity Ratio 0.00
Volume 1,188,193
Avg Vol 1,509,550
Day's Range N/A - N/A
Shares Out 253.72M
Stochastic %K 82%
Beta 0.36
Analysts Strong Sell
Price Target $490.00

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
JDR1983
JDR1983 Nov. 14 at 7:47 PM
Is $VRTX going to buy CRSP?
0 · Reply
svertical1
svertical1 Nov. 14 at 7:25 PM
$VRTX Priced right, Journavx can capture the category. Pain is ripe for solution! https://apple.news/AVzkcf-GyQc-Bj8C6PLWvbA
0 · Reply
svertical1
svertical1 Nov. 14 at 4:39 PM
$VRTX Nice breakout from wedge and close to challenging 200 day MA. Next gap fills at $462 & $500. http://www.finviz.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 2:57 AM
$VRTX is currently trading at $434.52, exhibiting a bullish sentiment as indicated by an RSI of 61.13, which suggests upward momentum but is approaching overbought territory. The price is above both the 30-day moving average (MA30) of 418.13 and the 50-day moving average (MA50) of 407.22, reinforcing a positive trend. The recent 60-day high of 441.17 indicates potential resistance, while the 60-day low of 374.17 provides a solid support level. For a trade plan, consider entering a long position at $435.00. Set a stop loss at $422.00 to manage risk. Target the first profit at $441.00, near the 60D high, and a second target at $450.00, which provides a psychological resistance level. This plan aligns with the current bullish trend while allowing for potential profit capture. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Nov. 13 at 9:12 PM
Raymond James🏁 $MAZE Outperform/$48 $VRTX $UNCY $OTSKY Raymond James said: The Maze Compass platform leverages genetic insights to discover novel therapies for genetically validated targets. MAZE's lead wholly-owned assets target high unmet need chronic kidney disease (CKD) populations: MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease (AMKD), and MZE782, an oral SLC6A19 inhibitor entering Phase 2 in phenylketonuria (PKU) and CKD. Both assets have best-in-class potential in attractive commercial indications and encouraging early mechanistic de-risking, in our view. While shares have roughly doubled from the January 2025 IPO, we believe MAZE continues to offer a very compelling risk/ reward skew into key Phase 2 readouts for MZE829 and MZE782 beginning in 2026.
0 · Reply
alphadog10
alphadog10 Nov. 13 at 6:34 PM
$LCTX vs $SANA vs $IPSC for islet cells. Don't mention $VRTX whos leading the pack and will dominate the space. Pretty positive LCTX and ipsc dont stand a chance in T1D development. Makes for a good PR though...
0 · Reply
svertical1
svertical1 Nov. 13 at 4:02 PM
$VRTX Vertex Pipeline is way underestimated by WS. https://www.foxnews.com/health/killer-condition-lands-top-10-leading-causes-death-global-cases-surge
0 · Reply
alwest228
alwest228 Nov. 13 at 1:23 AM
$VRTX on its way up!
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:02 AM
$VRTX: The last close at $427.14 indicates a position near the 60D high of $432.76, suggesting potential resistance. The RSI at 50.62 shows neutral momentum, indicating neither overbought nor oversold conditions. The MA30 at $416.2 and MA50 at $405.68 suggest a bullish trend, as the price is above both moving averages. However, the absence of a MA200 limits long-term trend analysis. Directional bias leans slightly bullish due to the proximity to recent highs and the support from the moving averages. Suggested entry is at $428.00, with a stop loss set at $415.00 to manage risk. Target 1 is $435.00, just above the 60D high, and Target 2 is $440.00, allowing for potential breakout gains. Monitor price action closely around the entry point and adjust targets as necessary based on market conditions. https://privateprofiteers.com
0 · Reply
WAJeff
WAJeff Nov. 12 at 4:25 PM
$VRTX starting to wake up
0 · Reply
Latest News on VRTX
Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 10 days ago

Committee stocks on the move: Uber and Vertex Pharma

UBER


Columbia Balanced Fund Q3 2025 Portfolio Update

Nov 4, 2025, 2:30 AM EST - 10 days ago

Columbia Balanced Fund Q3 2025 Portfolio Update

EA EBAY ELV INTU TEL


Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 11 days ago

Vertex Reports Third Quarter 2025 Financial Results


Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

Oct 28, 2025, 11:59 AM EDT - 17 days ago

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings


Vertex Announces Key Advancements Across Kidney Portfolio

Sep 25, 2025, 7:45 AM EDT - 7 weeks ago

Vertex Announces Key Advancements Across Kidney Portfolio


Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 2 months ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST


Vertex to Participate in Upcoming September Investor Conferences

Aug 20, 2025, 4:00 PM EDT - 3 months ago

Vertex to Participate in Upcoming September Investor Conferences


Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

Aug 12, 2025, 2:34 PM EDT - 3 months ago

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet


Weakness In Vertex Stock Seen As Buying Opportunity

Aug 5, 2025, 2:05 PM EDT - 3 months ago

Weakness In Vertex Stock Seen As Buying Opportunity


Vertex Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:01 PM EDT - 3 months ago

Vertex Reports Second Quarter 2025 Financial Results


How Will VRTX Stock React To Its Upcoming Earnings?

Aug 2, 2025, 12:20 AM EDT - 3 months ago

How Will VRTX Stock React To Its Upcoming Earnings?


JDR1983
JDR1983 Nov. 14 at 7:47 PM
Is $VRTX going to buy CRSP?
0 · Reply
svertical1
svertical1 Nov. 14 at 7:25 PM
$VRTX Priced right, Journavx can capture the category. Pain is ripe for solution! https://apple.news/AVzkcf-GyQc-Bj8C6PLWvbA
0 · Reply
svertical1
svertical1 Nov. 14 at 4:39 PM
$VRTX Nice breakout from wedge and close to challenging 200 day MA. Next gap fills at $462 & $500. http://www.finviz.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 2:57 AM
$VRTX is currently trading at $434.52, exhibiting a bullish sentiment as indicated by an RSI of 61.13, which suggests upward momentum but is approaching overbought territory. The price is above both the 30-day moving average (MA30) of 418.13 and the 50-day moving average (MA50) of 407.22, reinforcing a positive trend. The recent 60-day high of 441.17 indicates potential resistance, while the 60-day low of 374.17 provides a solid support level. For a trade plan, consider entering a long position at $435.00. Set a stop loss at $422.00 to manage risk. Target the first profit at $441.00, near the 60D high, and a second target at $450.00, which provides a psychological resistance level. This plan aligns with the current bullish trend while allowing for potential profit capture. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Nov. 13 at 9:12 PM
Raymond James🏁 $MAZE Outperform/$48 $VRTX $UNCY $OTSKY Raymond James said: The Maze Compass platform leverages genetic insights to discover novel therapies for genetically validated targets. MAZE's lead wholly-owned assets target high unmet need chronic kidney disease (CKD) populations: MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease (AMKD), and MZE782, an oral SLC6A19 inhibitor entering Phase 2 in phenylketonuria (PKU) and CKD. Both assets have best-in-class potential in attractive commercial indications and encouraging early mechanistic de-risking, in our view. While shares have roughly doubled from the January 2025 IPO, we believe MAZE continues to offer a very compelling risk/ reward skew into key Phase 2 readouts for MZE829 and MZE782 beginning in 2026.
0 · Reply
alphadog10
alphadog10 Nov. 13 at 6:34 PM
$LCTX vs $SANA vs $IPSC for islet cells. Don't mention $VRTX whos leading the pack and will dominate the space. Pretty positive LCTX and ipsc dont stand a chance in T1D development. Makes for a good PR though...
0 · Reply
svertical1
svertical1 Nov. 13 at 4:02 PM
$VRTX Vertex Pipeline is way underestimated by WS. https://www.foxnews.com/health/killer-condition-lands-top-10-leading-causes-death-global-cases-surge
0 · Reply
alwest228
alwest228 Nov. 13 at 1:23 AM
$VRTX on its way up!
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:02 AM
$VRTX: The last close at $427.14 indicates a position near the 60D high of $432.76, suggesting potential resistance. The RSI at 50.62 shows neutral momentum, indicating neither overbought nor oversold conditions. The MA30 at $416.2 and MA50 at $405.68 suggest a bullish trend, as the price is above both moving averages. However, the absence of a MA200 limits long-term trend analysis. Directional bias leans slightly bullish due to the proximity to recent highs and the support from the moving averages. Suggested entry is at $428.00, with a stop loss set at $415.00 to manage risk. Target 1 is $435.00, just above the 60D high, and Target 2 is $440.00, allowing for potential breakout gains. Monitor price action closely around the entry point and adjust targets as necessary based on market conditions. https://privateprofiteers.com
0 · Reply
WAJeff
WAJeff Nov. 12 at 4:25 PM
$VRTX starting to wake up
0 · Reply
JamesGuthrie503
JamesGuthrie503 Nov. 12 at 3:12 PM
$VRTX leads biotech innovation in cystic fibrosis and genetic therapies with strong cash generation. AERT recently turned profitable in Q2 FY2026, reporting $17.36 M revenue and $0.64 M net income, highlighting momentum in its AI-led global delivery model. https://www.youtube.com/watch?v=d2BieklTnl4
0 · Reply
alwest228
alwest228 Nov. 12 at 3:57 AM
$VRTX Just had major surgery and was prescribed Journavx. I had absolutely NO pain. This stock is going to blow up soon!
0 · Reply
svertical1
svertical1 Nov. 12 at 1:09 AM
$IBRX $CADL $XBI $VRTX $CRSP Great post! Shouldn’t need to be famous or Royalty to get proven drugs.
1 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:39 AM
$VRTX: The last close at $427.14 indicates a position near the 60D high of $432.76, suggesting potential resistance. The RSI at 50.62 shows neutral momentum, indicating neither overbought nor oversold conditions. The MA30 at $416.2 and MA50 at $405.68 suggest a bullish trend, as the price is above both moving averages. However, the absence of a MA200 limits long-term trend analysis. Directional bias leans slightly bullish due to the proximity to recent highs and the support from the moving averages. Suggested entry is at $428.00, with a stop loss set at $415.00 to manage risk. Target 1 is $435.00, just above the 60D high, and Target 2 is $440.00, allowing for potential breakout gains. Monitor price action closely around the entry point and adjust targets as necessary based on market conditions. https://privateprofiteers.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 11 at 6:04 PM
1 · Reply
Quantumup
Quantumup Nov. 10 at 3:05 PM
H.C. Wainwright⬆️Top Pick $VERA's PT to $90 from $85 and reiterated at a Buy rating. $OTSKY $VRTX H.C. Wainwright in its note said: On November 6, Vera, one of HCW 2H25 Top Picks, presented key findings from its ongoing pivotal ORIGIN 3 study with atacicept during the opening plenary session of the 2025 American Society of Nephrology (ASN) Kidney Week and hosted a conference call to review the data with two distinguished KOLs in immunoglobulin A nephropathy (IgAN). Given the totality of atacicept's robust data set, we expect the FDA to accept the BLA for review through the Accelerated Approval pathway, and we believe atacicept is highly likely to be approved in 2026. As a result, we are increasing our probability of launch for atacicept in IgAN to 95% from 90%. We currently project the drug to generate risk-adjusted revenues of $56M in 2026, growing to $2.5B by 2033. Consequently, we are raising our price target of VERA to $90 from $85.
0 · Reply
biolover
biolover Nov. 10 at 2:36 PM
$VKTX Names would be $VRTX $INSM $BIIB that want to get to mega size
0 · Reply
Goldenpoint9
Goldenpoint9 Nov. 10 at 1:49 PM
0 · Reply
Quantumup
Quantumup Nov. 10 at 1:15 PM
BofA reit'd $VERA Buy-$48, and said, 'ASN Takeaways: KOL Support for Atacicept is Remarkable—NEJM: Atacicept Detailed Ph3 Interim Data Sets High Bar' $OTSKY $VRTX BofA added:
0 · Reply
JoeB07
JoeB07 Nov. 8 at 10:20 PM
$INSM We're still undervalued! UBS hits the nail on the head.... "at these levels, stock (INSM) is not pricing in much for pipeline upside from CRSsNP, HS for brenso and TPIP indications." ... not to mention Arikayce label expansion! Great write-up and super excited to see the first full Q of Brensupri sales at JPM in January. $LLY $MRK $VRTX
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 6:24 PM
UBS updates rating for Vertex Pharmaceuticals ( $VRTX ) to Buy, target set at 553 → 546.
1 · Reply
maq34
maq34 Nov. 7 at 3:56 PM
$ATRC Raised 2025 Financial Outlook: Building on the strong results, AtriCure raised its full-year 2025 revenue projection to a range of $532 million to $534 million, and its adjusted EBITDA forecast to between $55 million and $57 million. PT of $54 and up…! $AMGN $ABBV $VRTX $GILD
0 · Reply